IP Verse

Cytokine Derived Treatment With Reduced Vascular Leak Syndrome - EP2986312

The patent EP2986312 was granted to Cytune Pharma on Dec 15, 2021. The application was originally filed on Apr 22, 2014 under application number EP14723324A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2986312

CYTUNE PHARMA
Application Number
EP14723324A
Filing Date
Apr 22, 2014
Status
Granted And Under Opposition
Nov 12, 2021
Publication Date
Dec 15, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANOFISep 14, 2022ZWICKERADMISSIBLE
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBSep 14, 2022WICHMANNADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTEP2511294
INTERNATIONAL-SEARCH-REPORTUS2009238791
INTERNATIONAL-SEARCH-REPORTWO2012175222
OPPOSITIONEP2511294
OPPOSITIONUS2012177595
OPPOSITIONWO2007001677
OPPOSITIONWO2009002562
OPPOSITIONWO2012175222
OPPOSITIONWO2014170032

Non-Patent Literature (NPL) Citations (10) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
INTERNATIONAL-SEARCH-REPORT- BESSARD A ET AL, "High antitumor activity of RLI, an IL15-IL15Ralpha fusion protein, in metastatic melanoma and colorectal cancer", CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US, vol. 48, no. 1-2, doi:10.1016/J.CYTO.2009.07.442, ISSN 1043-4666, (20091001), page 105, (20090918), XP026624805 [Y] 1-29 * abstract *
INTERNATIONAL-SEARCH-REPORT- ANNE BESSARD ET AL, "High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, (20090901), vol. 8, no. 9, doi:10.1158/1535-7163.MCT-09-0275, ISSN 1535-7163, pages 2736 - 2745, XP002636846 [Y] 1-29 * abstract * * page 2737, columns 3,4,9 * * page 2741, columns 3,6 * * page 2742, column 4 * * page 2744, column 1 *
OPPOSITION- Anonymous, "Body Weight Information for C57BL/6J (000664)", The Jackson Laboratory, (20220000), pages 1 - 3, XP055967277
OPPOSITION- Anonymous, "Guidance for Industry - Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers", FDA guidance, (20050000), pages 1 - 30, XP055294866
OPPOSITION- Fda, "Guidance for Industry - Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers", (20050701), pages 1 - 27, URL: https://www.fda.gov/media/72309/download, (20200609), XP055702805
OPPOSITION- REAGAN-SHAW et al., "Dose translation from animal to human studies revisited", Reagan-Shaw S; Nihal M; Nihal N, (20080300), vol. 22, no. 3, pages 659 - 661, XP007916336
OPPOSITION- E. Chertova, C. Bergamaschi, O. Chertov, R. Sowder, J. Bear, J. D. Roser, R. K. Beach, J. D. Lifson, B. K. Felber, G. N. Pavlakis, "Characterization and Favorable in Vivo Properties of Heterodimeric Soluble IL-15{middle dot}IL-15R  Cytokine Compared to IL-15 Monomer", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, (20130621), vol. 288, no. 25, doi:10.1074/jbc.M113.461756, ISSN 00219258, pages 18093 - 18103, XP055134195
OPPOSITION- Mortier Erwan, Quéméner Agnès, Vusio Patricia, Lorenzen Inken, Boublik Yvan, Grötzinger Joachim, Plet Ariane, Jacques Yannick, "Soluble Interleukin-15 Receptor α (IL-15Rα)-sushi as a Selective and Potent Agonist of IL-15 Action through IL-15Rβ/γ", J Biol Chem, (20060120), vol. 281, no. 3, pages 1612 - 1619, XP002394330
OPPOSITION- Conlon Kevin, Watson Dionysios C, Waldmann Thomas A, Valentin Antonio, Bergamaschi Cristina, Felber Barbara K, Peer Cody J, Figg William D, Potter E Lake, Roederer Mario, Mcneel Douglas G, Thompson John A, Gupta Sumati, Leidner Rom, Wang-Gillam Andrea, Parikh Nehal S, Long Debby, Kurtulus Sema, Ho Lee Lang, Chowdhury Niladri Roy, Bender Florent, Pavlakis George N, "Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors", Journal for ImmunoTherapy of Cancer, BMJ Publishing Group, (20211101), vol. 9, no. 11, doi:10.1136/jitc-2021-003388, page e003388, XP055964474
OPPOSITION- Anne Bessard; Véronique Solé; Grégory Bouchaud; Agnès Quéméner; Yannick Jacques, "High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer", Mol Cancer Ther, (20090900), vol. 8, no. 9, pages 2736 - 2745, XP002636846

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents